New data on botulinum toxin as treatment for nerve pain

Botulinum toxin could offer an efficient brand-new treatment for two forms of neuropathy — pain caused by various types of nerve injury, according to an experimental study published in Anesthesia & Analgesia.

Treatment along with botulinum toxin type B (BoNT-B) produces lasting reduction in abnormal pain responses caused by bodily nerve injury or chemotherapy-related nerve damage in mice, reports Tony L. Yaksh, Ph.D., of University of California, San Diego, and colleagues. Their study shows differing effects of local versus spinal injection of botulinum toxin and lends brand-new insights in to the molecular-degree explanations for exactly how “Botox” works to affect pain processing.

Further Studies on Botulinum Toxin’s Effects on Pain Responses

Building on previous studies, the researchers performed experiments in mice to evaluate the effects of BoNT-B on exaggerated pain responses to touch (allodynia) in one or the 2 hind paws after nerve injury. Mononeuropathy (single nerve injury) was induced by cutting a single spinal nerve and polyneuropathy (multiple nerve injury) by giving the chemotherapy drug cisplatin.

For the 2 types of neuropathy, the study evaluated the effects of injecting BoNT-B directly in to the affected paw or in to the spine (intrathecal injection). Botulinum toxin is most familiar from the use of BoNT-A — frequently known by the trade name Botox — for cosmetic plastic surgery. the 2 BoNT-A and BoNT-B are used for treatment of various neuromuscular disorders.

Over the past decade, BoNT-A has actually been successfully used to treat certain chronic pain syndromes. Because botulinum toxin sets off temporary muscle paralysis, the pain-lowering effects have actually been attributed to muscle relaxation. However, recent studies have actually suggested that various other analgesic mechanisms might be operating as well.

In mononeuropathy, injecting BoNT-B in to the affected paw significantly low abnormal pain responses. In polyneuropathy, local BoNT-B injection low allodynia in the injected paw only. This shows that the effects of locally injected botulinum toxin aren’t because of a lot more general spread of the toxin.

The reduction in allodynia after local BoNT-B injection lasted concerning two weeks prior to wearing off. That’s consistent along with the temporary effect of botulinum toxin used for various other purposes — the injections need to be repeated to sustain the useful effects.

In polneuropathy, intrathecal injection of BoNT-B relieved the allodynia on the 2 affected sides. Spinal BoNT-B didn’t transform normal reflexes in the paws, and didn’t transform various other types of pain perception.

Cellular-degree studies showed that both types of BoNT-B injection had differing effects in the pain-processing centers of the spinal cord. The outcomes offered brand-new insights in to the personal molecular targets involved in local and intrathecal injection.

Neuropathies are common and difficult-to-treat chronic pain problems. Mononeuropathy outcomes from nerve injury of several feasible sets off — for example, spinal cord injury or various other trauma. Polyneuropathy can easily occur as a toxic effect of chemotherapy drugs, even though diabetes is the most common cause.

The findings include to previous studies suggesting that botulinum toxin could be a helpful brand-new approach to treating neuropathic pain. They aid in learning BoNT’s mechanisms of action in mononeuropathy versus polyneuropathy, as well as the differing effects of local and spinal injection.

The study is additionally one he very first to concentrate on BoNT-B, which is shorter-acting compared to BoNT-A. Dr. Yaksh and colleagues conclude, “Further job focusing on transport and uptake of these and various other BoNT serotypes will certainly most likely give vital insights in to the mechanisms whereby these toxins exert their effects upon nociceptive [pain] processing.”

Story Source:

The above article is reprinted from materials offered by International Anesthesia Research Society (IARS). Note: components might be edited for content and length.

Sorrento Announces Departure of Mr. George Uy to become CEO of Start-up Company






<!– imageTag: –>
<!– imageTagafter: and imageUrl: http://photos.prnewswire.com/prnvar/20150105/167173LOGO?max=400 –>















SAN DIEGO, July 17, 2015 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company creating brand-new treatments for cancer and its associated pain, announced today that Mr. George Uy, Executive Vice President and Chief Commercial Officer, will certainly be leaving the Company at the end of July 2015 to join a start-up company as its Chief Executive Officer. 

Mr. Uy was the Chief Commercial Officer of IgDraSol, Inc., a private company creating Cynviloq™ (paclitaxel polymeric-bound micelle) under the 505(b)(2) registrational pathway, which became a wholly-owned subsidiary of Sorrento in 2013. Several transformational events occurred throughout Mr. Uy’s tenure at Sorrento including the up-listing of Sorrento common stock to NASDAQ, considerable capital raises, a lot of corporate strategic partnerships and acquisitions, including the CAR.TNK collaboration along with ConkWest (now known as NantKwest), the formation of the Nantibody JV, the immunotherapy collaboration along with NantCell, the M&A of Sherrington Pharma along with the clinical stage asset resiniferatoxin (RTX), and the recent acquisition of Cynviloq by NantPharma, a NantWorks affiliated company, adhering to the successful conclusion of the bio-equivalence TRIBECA™ registration trial.  

Mr. Uy will certainly go on to offer strategic suggestions to the Company as a consultant start August 1, 2015. “We regret George’s departure, yet wish him or her the most effective in his placement as CEO of a brand-new venture,” said Dr. Henry Ji, President and Chief Executive Officer at Sorrento. “We thank George for every one of his past contributions and anticipate his continued involvement as our strategic advisor.”

About Sorrento Therapeutics, Inc. 

Sorrento is a clinical stage oncology company creating brand-new treatments for cancer and associated pain. Sorrento recently sold the rights to Cynviloq, which successfully completed the TRIBECA study, to NantPharma. The company is additionally creating resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to manage terminal cancer patients suffering from intractable pain.

In December 2014, Sorrento and NantWorks formed a global joint venture, now called Nantibody, to concentrate on immunotherapies for cancer. additionally in December 2014, Sorrento and NantKwest, Inc., an immuno-oncology company creating proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, entered in to an agreement to jointly create CAR.TNK™ (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases. In March 2015, Sorrento entered in to a global collaboration along with NantCell, a NantWorks company, to locate and create immunotherapies versus tumor neo-epitopes.  In July 2015, Sorrento and NantBioScience, Inc., a subsidiary of NantWorks, established a joint venture, called NantCancerStemCell to concentrate on the development of “first-in-class” small molecules versus targets which might treat crucial drivers of cancer growth including cancer stem cells.

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could trigger actual outcomes to differ materially from those projected. Forward-looking statements consist of statements Concerning Sorrento’s prospects, including, yet not limited to any sort of statements Concerning obtaining regulatory approval, Sorrento’s expectations for adoptive cellular immunotherapies and Sorrento’s collaborations along with NantKwest, Nantibody and Nantcell; Sorrento’s ability to leverage the expertise of its employees and partners to aid the company in the execution of its strategies; Sorrento’s advances gained in creating RTX, CAR.TNKs and human monoclonal antibodies using its proprietary G-MAB fully human antibody technology, if any; and various other matters that are described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent Quarterly Reports on Form 10-Q filed along with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any sort of forward-looking statement in this press release except as needed by law.

Sorrento™, GMAB™, CAR.TNK™, and the Sorrento logo are trademarks owned by Sorrento Therapeutics, Inc.

All various other trademarks and trade names are the property of their respective owners.

Logo – http://photos.prnewswire.com/prnh/20150105/167173LOGO

 

SOURCE Sorrento Therapeutics, Inc.

RELATED LINKS
http://www.sorrentotherapeutics.com

Action spectrum of sun skin damage documented

Scientists at Newcastle University have actually documented for the very first time the DNA damage which can easily occur to skin across the complete range of ultraviolet radiation from the sun offering an invaluable device for sun-protection and the manufacturers of sunscreen.

Testing on human skin cell lines, this study published in The Society for Investigative Dermatology, documents the action spectrum of ultraviolet damage in cells derived from the 2 the top layer (dermis) and lesser layer (epidermis) of the skin.

This will certainly permit manufacturers of sunscreen to create and test products to ensure that they can easily give protection to the 2 layers.

Our skin ages as a result of the constant exposure to sunlight as ultraviolet radiation comprising UVA and UVB rays from the sun penetrates cells and boosts the variety of damaging free radicals, especially the reactive oxygen species. also lots of reactive oxygen species can easily be harmful due to the fact that they can easily damage the DNA within our cells.

Over time, this can easily bring about the accumulation of DNA damage, particularly in mitochondria — the batteries of the cells — which rate up aging and ruin the skin’s supportive fibres, collagen and elastin, best to wrinkles. Studies strongly suggest the damage caused by reactive oxygen species might likewise initiate and exacerbate the progression of skin cancers.

Professor Mark Birch-Machin, Professor of Molecular Dermatology at Newcastle University said: “due to the fact that we were able to analyse the complete spectrum of UVA and UVB induced sunburnt DNA damage in the batteries of human skin cells this is an invaluable device for the cosmetic and pharmaceutical industries and for anti-aging studies.”

The Engineering and Bodily Sciences Research Council funded Dr Jennifer Latimer as a CASE PhD Student at Newcastle University for the job alongside a funding award for the collaboration along with Proctor and Gamble.

Dr Latimer said: “It is delightful to believe that four years of scientific research has actually resulted in an outcome that is potentially beneficial, not just to the scientific community however likewise to industry and the total public.”

Story Source:

The above article is reprinted from materials offered by Newcastle University. Note: contents could be edited for content and length.

Cosmetic lip surgery may ease facial paralysis, small study suggests

A cosmetic surgery that uses injections of hyaluronic acid to make lips appear fuller could likewise increase the lives of people along with facial paralysis, according to outcomes of a small study by researchers at Johns Hopkins and Stanford universities.

Facial paralysis triggers the two bodily and psychological problems, says Kofi Boahene, M.D., a facial plastic and reconstructive surgeon in the Department of Otolaryngology-Head and Neck Surgery at the Johns Hopkins University School of Medicine and an author of a published report concerning the study appearing June 18 in the diary JAMA Facial Plastic Surgery. “It’s a quite large problem,” he notes, “that can easily occur as a result of stroke, Bell’s Palsy, muscular dystrophy, trauma and birth defects.”

Without lip control, patients struggle along with drooling, consuming and drinking Free of spillage, and making sounds that require fully closing the lips, such as words containing the letters “b” and “p.” Numerous people along with facial paralysis likewise become self-conscious concerning exactly how they look.

Boahene says he stumbled across a feasible role for hyaluronic acid injection while functioning along with a patient along with a then-undiagnosed case of muscular dystrophy. Her face was weak, and she had trouble speaking. To increase her lip muscle tone, he tried the injection and says the effects were immediate. Her face appeared stronger, and her articulation markedly improved.

“To preserve structure, plants fill their leaves and stems along with water,” Boahene says. “It’s a crude analogy, yet injecting the lips along with hyaluronic acid works in a lot the very same way. It tones the tissue surrounding the muscle.”

To test the procedure, Boahene and his collaborators recruited 22 patients (14 women and eight men) along with facial paralysis on one edge of the mouth along along with three patients along with muscular dystrophy that had lost manage of the two sides of the mouth.

Baseline measures of lip tone were performed by having participants place their lips about an instrument that measured tension and took readings from the left, middle, and right sides of the mouth. (The three patients along with muscular dystrophy endured from uniform weakness across the lips, while the rest of the patients had lost manage on one edge only). The researchers after that identified the weakest points by having participants blow air along with pursed lips. At points where air escaped, the researchers injected the hyaluronic acid.

Boahene says the findings were striking, along with the greatest improvement seen in the three patients along with muscular dystrophy, whose lip strength increased six- to sevenfold over the original reading. For participants along with paralysis on only one edge of the mouth, lip strength increased an standard of 1.4-fold on the paralyzed edge and 0.4-fold on the unaffected side.

To see exactly how well those improvements carried over to everyday life needs, a speech therapist conducted a before-and-after assessment of the patients’ ability to speak and to consume and drink Free of spilling. all of 25 patients showed marked improvement, Boahene says. Plans are underway to confirm the benefits in a larger study along with concerning 100 patients.

The effects of the injections, which cost between $500 and $2,000, are temporary, lasting concerning a year once done for cosmetic purposes. once done for cosmetic improvement, insurance usually does not cover the bill. However, insurance companies usually make an exception once the benefits are primarily therapeutic, Boahene says. Lip injection is a minimally invasive outpatient procedure that can easily be performed by dermatologists and plastic surgeons; however, Boahene says, it is vital that therapeutic injections be performed by physicians went through in treating and managing facial paralysis and muscle weakness.

Boahene says that if the 25 patients go on to reveal improvement Free of any kind of marked edge effects, he could pursue examinations of longer-lasting solutions, such as removing fat from elsewhere in the physique and injecting it about the mouth.

Moreover, he says, the procedure might likewise guidance patients whose facial nerves have actually been repaired yet that demand temporary lip guidance while full healing from such repairs occurs.

Story Source:

The above information is reprinted from materials offered by Johns Hopkins Medicine. Note: contents could be edited for content and length.

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2015 Financial Results






SOUTH PLAINFIELD, N.J., July 16, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Firm will certainly host a webcast conference call to report its second quarter 2015 financial outcomes and give an update on the company’s company and outlook on Thursday, July 30, 2015 at 4:30 p.m. (ET) after the closing of the market.

The call can easily be accessed by dialing (877) 303-9216 (domestic) or + 1 (973) 935-8152 (international) 5 moments prior to the begin of the call and supplying the passcode 86272093. A live, listen-just webcast of the conference call can easily be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will certainly be readily available around 2 hrs after completion of the call and will certainly be archived on the company’s website for 2 weeks.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical Firm focused on the discovery, progress and commercialization of orally administered, proprietary small molecule drugs targeting a spot of RNA biology we refer to as post-transcriptional control. Post-transcriptional regulate procedures are the regulatory events that occur in cells throughout and after a messenger RNA is copied from DNA through the transcription process. PTC’s internally found pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has actually found every one of its compounds currently under progress making use of its proprietary technologies. PTC strategies to keep on to create these compounds the 2 on its own and through selective collaboration arrangements along with best pharmaceutical and biotechnology companies. For a lot more article on the company, please visit our website www.ptcbio.com.

For a lot more Information:

Investors:
Emily Hill
+1 (908) 912-9327
ehill@ptcbio.com

Media:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com

SOURCE PTC Therapeutics, Inc.

RELATED LINKS
http://www.ptcbio.com